Recent developments in cyclin-dependent kinase biochemical and structural studies.

The cyclin-dependent kinases (CDKs) have been intensely studied because of their involvement in regulating essential cellular activities that include proliferation and transcription. A series of CDK2-containing structures have informed a general model for the molecular details of CDK activation and regulation. Recent structural studies of other members of the CDK family have lead to a re-appraisal of this model. In this review, we describe alternative CDK-cyclin assemblies taking the recently characterised CDK/cyclin complexes, CDK9/cyclinT1 and CDK4/cyclinD as examples. The differential effects of CDK phosphorylation on CDK activation state and substrate specificity are examined in the light of recent data on CDK2/cyclinA, CDK9/cyclinT, CDK4/cyclinD and Pho85/Pho80. We also present an overview of factors that affect CDK substrate specificity, and, in particular, the contributions that are made by the cyclin subunit. Finally, we review recent results that have helped to unravel the molecular mechanisms underlying the conflicting roles of the Cip/Kip CDK inhibitor family in CDK regulation.

[1]  K. Henrick,et al.  Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.

[2]  S. Blain,et al.  Differential Modification of p27Kip1 Controls Its Cyclin D-cdk4 Inhibitory Activity , 2007, Molecular and Cellular Biology.

[3]  J. LaBaer,et al.  New functional activities for the p21 family of CDK inhibitors. , 1997, Genes & development.

[4]  D O Morgan,et al.  Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.

[5]  Pierre Dubus,et al.  Cdk1 is sufficient to drive the mammalian cell cycle , 2007, Nature.

[6]  M. Noble,et al.  Structures of P. falciparum protein kinase 7 identify an activation motif and leads for inhibitor design. , 2008, Structure.

[7]  S. Elledge,et al.  The DNA damage response: putting checkpoints in perspective , 2000, Nature.

[8]  J. Slingerland,et al.  Phosphorylation of p27Kip1 Regulates Assembly and Activation of Cyclin D1-Cdk4 , 2008, Molecular and Cellular Biology.

[9]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. P. Fisher,et al.  p27Kip1 Inhibits Cyclin D-Cyclin-Dependent Kinase 4 by Two Independent Modes , 2008, Molecular and Cellular Biology.

[11]  Ivo Tews,et al.  Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. , 2002, Biochemistry.

[12]  L. Johnson,et al.  Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2. , 2001, Molecular cell.

[13]  M. Noble,et al.  How Tyrosine 15 Phosphorylation Inhibits the Activity of Cyclin-dependent Kinase 2-Cyclin A* , 2007, Journal of Biological Chemistry.

[14]  D. Takeda,et al.  Mutational Analysis of the Cy Motif from p21 Reveals Sequence Degeneracy and Specificity for Different Cyclin-Dependent Kinases , 2001, Molecular and Cellular Biology.

[15]  L. Johnson,et al.  Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product. , 1995, Structure.

[16]  D. Morgan,et al.  Reciprocal Activation by Cyclin-Dependent Kinases 2 and 7 Is Directed by Substrate Specificity Determinants outside the T Loop , 2001, Molecular and Cellular Biology.

[17]  Catherine G. Takizawa,et al.  Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. , 2000, Current opinion in cell biology.

[18]  N. Pavletich,et al.  Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. , 2000, Genes & development.

[19]  L. Johnson,et al.  The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2‐independent roles , 2005, The EMBO journal.

[20]  R. Fisher.  Secrets of a double agent: CDK7 in cell-cycle control and transcription , 2005, Journal of Cell Science.

[21]  L. Johnson,et al.  Cyclin B and Cyclin A Confer Different Substrate Recognition Properties on CDK2 , 2007, Cell cycle.

[22]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[23]  L. Johnson,et al.  The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases , 1999, Nature Cell Biology.

[24]  L. Tsai,et al.  Structure and regulation of the CDK5-p25(nck5a) complex. , 2001, Molecular cell.

[25]  M. Barbacid,et al.  Mammalian cyclin-dependent kinases. , 2005, Trends in biochemical sciences.

[26]  Peter M Fischer,et al.  Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. , 2008, Trends in pharmacological sciences.

[27]  L. Johnson,et al.  The structure of P‐TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation , 2008, The EMBO journal.

[28]  P. Kaldis,et al.  Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms , 2009, Oncogene.

[29]  Martin E M Noble,et al.  The Role of the Phospho-CDK2/Cyclin A Recruitment Site in Substrate Recognition* , 2006, Journal of Biological Chemistry.

[30]  J. Koča,et al.  Different Mechanisms of CDK5 and CDK2 Activation as Revealed by CDK5/p25 and CDK2/Cyclin A Dynamics* , 2006, Journal of Biological Chemistry.

[31]  Rajiv Chopra,et al.  Crystal structure of human CDK4 in complex with a D-type cyclin , 2009, Proceedings of the National Academy of Sciences.

[32]  M. E. M. Noble,et al.  The structure of CDK4/cyclin D3 has implications for models of CDK activation , 2009, Proceedings of the National Academy of Sciences.

[33]  N. Hayward.  Genetics of melanoma predisposition , 2003, Oncogene.

[34]  Yan Geng,et al.  Cyclin E Ablation in the Mouse , 2003, Cell.

[35]  Geoffrey J. Barton,et al.  The Jalview Java alignment editor , 2004, Bioinform..

[36]  Andrea Musacchio,et al.  Mechanism of CDK5/p25 binding by CDK inhibitors. , 2005, Journal of medicinal chemistry.

[37]  Shunichi Takeda,et al.  Cyclin-dependent kinases and cell-cycle transitions: does one fit all? , 2008, Nature Reviews Molecular Cell Biology.

[38]  James M. Roberts,et al.  Living with or without cyclins and cyclin-dependent kinases. , 2004, Genes & development.

[39]  M. Donzelli,et al.  Regulating mammalian checkpoints through Cdc25 inactivation , 2003, EMBO reports.

[40]  Zhou Songyang,et al.  Use of an oriented peptide library to determine the optimal substrates of protein kinases , 1994, Current Biology.

[41]  L. Johnson,et al.  CAK—Cyclin-Dependent Activating Kinase: A Key Kinase in Cell Cycle Control and a Target for Drugs? , 2005, Cell cycle.

[42]  J. Sobczak-Thépot,et al.  Delayed early embryonic lethality following disruption of the murine cyclin A2 gene , 1997, Nature Genetics.

[43]  L. Johnson.  Protein kinase inhibitors: contributions from structure to clinical compounds , 2009, Quarterly Reviews of Biophysics.

[44]  L. Tsai,et al.  Structure and Regulation of the CDK5-p25nck5a Complex , 2001 .

[45]  V. Hu.  The Cell Cycle , 1994, GWUMC Department of Biochemistry Annual Spring Symposia.

[46]  L. Tsai,et al.  Cdk5 behind the wheel: a role in trafficking and transport? , 2002, Trends in cell biology.

[47]  K. Shokat,et al.  Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics , 2006, Nature Structural &Molecular Biology.

[48]  J. Diffley,et al.  CDKs Promote DNA Replication Origin Licensing in Human Cells by Protecting Cdc6 from APC/C-Dependent Proteolysis , 2005, Cell.

[49]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[50]  Anindya Dutta,et al.  A Bipartite Substrate Recognition Motif for Cyclin-dependent Kinases* , 2001, The Journal of Biological Chemistry.

[51]  Structure of the Pho85-Pho80 CDK-cyclin complex of the phosphate-responsive signal transduction pathway. , 2007, Molecular cell.

[52]  K. Akashi,et al.  Mouse Development and Cell Proliferation in the Absence of D-Cyclins , 2004, Cell.

[53]  B. Suter,et al.  T‐loop phosphorylation stabilizes the CDK7–cyclin H–MAT1 complex in vivo and regulates its CTD kinase activity , 2001, The EMBO journal.

[54]  James M. Roberts,et al.  The p21Cip1 and p27Kip1 CDK ‘inhibitors’ are essential activators of cyclin D‐dependent kinases in murine fibroblasts , 1999, The EMBO journal.

[55]  N. Pavletich.  Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. , 1999, Journal of molecular biology.

[56]  Philip D. Jeffrey,et al.  Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complex , 1996, Nature.

[57]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[58]  Jaroslav Koča,et al.  Regulatory phosphorylation of cyclin-dependent kinase 2: insights from molecular dynamics simulations , 2008, Journal of molecular modeling.

[59]  T. Hunt,et al.  Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Martin E M Noble,et al.  Molecular Motions of Human Cyclin-dependent Kinase 2* , 2005, Journal of Biological Chemistry.

[61]  Jiri Bartek,et al.  Checking on DNA damage in S phase , 2004, Nature Reviews Molecular Cell Biology.